Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Iron Supplementation Effects on Vaccine Response in Iron Deficient Women
NCT06116669Recruiting
- Sponsor
- ETH Zurich
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ferrous sulfate in iron deficiency anemia (IDA) (3 arms), sponsored by ETH Zurich. Primary endpoints: Johnson & Johnson COVID-19 vaccine response at Day 56, Quadrivalent meningococcal vaccine response at Day 56 and 1 more. Started Nov 2023; status: recruiting.
02
Drugs
ferrous sulfate
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT06116669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116669.